Becton Dickinson announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample in the privacy of their own home. The program combines the Camtech Health HPV test for self-collection with the BD Onclarity HPV Assay, which is a clinically validated test that can simultaneously detect 14 high-risk HPV strains. The program objective is to improve the rate of cervical cancer screening in Singapore, where less than half of eligible women are currently being tested.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BDX:
- GD, BDX, SYY: 3 Best Dividend Aristocrats with Plenty of Upside Potential
- Becton Dickinson Issues Euro and USD Debt Notes
- Becton Dickinson Launches Billion-Dollar Note Offerings
- Becton Dickinson price target raised to $305 from $301 at Barclays
- Becton Dickinson ups FY24 adjusted EPS view to $12.82-$13.06 from $12.70-$13.00
